期刊文献+

硫辛酸联合恩再适治疗化疗药物致周围神经病变的疗效观察 被引量:14

Clinical Observation to Combination Treatment of Lipoic Acid and Analgecine for Chemotherapy-induced Peripheral Neuropathy
下载PDF
导出
摘要 目的观察硫辛酸联合恩再适治疗抗肿瘤药物所致周围神经病变的疗效。方法将43例恶性肿瘤化疗后周围神经病变患者,给予硫辛酸600 mg+恩再适7.2 U静脉滴注,1次/d,共2周。比较治疗前后患者临床症状和体征变化。结果治疗前后神经电生理检查,正中神经、腓总神经的神经传导速度(MCV)间差异均有统计学意义(P<0.05);治疗前患者视觉模拟评分(VAS)为(5.2±2.5)分,治疗后为(1.9±1.2)分,治疗前后比较差异有统计学意义(P<0.01);治疗后显效率为83.72%,总有效率为95.34%。结论硫辛酸与恩再适联用可显著改善恶性肿瘤化疗后的周围神经症状。 Objective To observe the clinical effect of Lipoic acid and Analgeeine on peripheral neuropathy induced by anticancer drugs. Methods Forty - three patients with chemotherapy - induced peripheral neuropathy were given lipoic acid (600 rag) with intravenous infusion of analgecine (7.2 U), once a day, 2 weeks. The changes of clinical symptoms and signs were compared between pre - and post - treatment. Results There was significant difference in MCV of median nerve and common peroneal between pre - and post - treatment ( P 〈 0. 05 ). The visual analogue scale ( VSA ) was ( 5.2 ± 2, 5 ) before treatment, and ( 1.9 ± 1.2) after treatment, the difference was significant (P 〈0. 01 ). The posttreatment efficiency was 83.72%, total effective rate 95. 34%. Conclusion Lipoic acid combined with analgecine can improve effectively the peripheral nerve symptoms after chemotherapy of malignant tumors.
出处 《中国全科医学》 CAS CSCD 北大核心 2010年第11期1232-1233,共2页 Chinese General Practice
关键词 恶性肿瘤 周围神经病变 硫辛酸 恩再适 Malignant tumor Peripheral neuropathy Lipoic acid Analgecine
  • 相关文献

参考文献9

  • 1李宇清,梅开勇,杜志强,江素华,曾波航.肿瘤化疗神经毒性及其治疗的临床研究[J].国际医药卫生导报,2006,12(15):14-17. 被引量:19
  • 2梁昱.抗肿瘤化疗药物所致的神经毒性研究进展[J].临床内科杂志,2006,23(6):430-432. 被引量:27
  • 3Pinedo DM,Shah-Khan F,Shah PC.Reversible posterior leukoencephalopathy syndrome associated with oxaliplatin[J].J Clin Oncol,2007,25(33):5320-5321.
  • 4Flatters SJ,Bennett GJ.Ethosuximide reverses paclitaxel and vincristine-induced painful peripheral neuropathy[J].Pain,2004,109(1-2):150-161.
  • 5Bardos G,Moricz K,Jaszlits L,et al.BGP-15,a hydroximic acid derivative,protects against cisplatin-or taxol-induced peripheral neuropathy in rats[J].Toxicol Appl Pharmaco1,2003,190(1):9-16.
  • 6Von Delius S,Eckel F,Wagenpfeil S.Carbamazepine for prevention of oxaliplatin-related neurotoxicity in patients with advanced colorectal cancer:final results of a randomised,controlled,multicenter phase Ⅱ study[J].Invest New Drugs,2007,25(2):173-180.
  • 7Rao RD,Michalak JC,Sloan JA,et al.Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy:a phase 3 randomized,double-blind,placebo-controlled,crossover trial[J].Cancer,2007,110(9):2110-2118.
  • 8Effects of ramipril on cadiovascular and microvascular outcomes in people with diabetes mellitus:results of the HOPE study and MICRO-HOPE substudy.Heart Outcomes Prevention Evaluation Study Investigators[J].Lancet,2000,355(9200):253-259.
  • 9杨为,唐勇,吴燕峰,沈慧勇.恩再适治疗神经病理性疼痛的临床应用[J].中国现代医药杂志,2008,10(5):61-62. 被引量:16

二级参考文献31

  • 1唐勇,杨为,黄霖,杨睿,史玉朋,贺晓玉,沈慧勇.恩再适治疗腰椎间盘突出引起的神经根性疼痛的临床观察[J].中国医药,2006,1(12):743-744. 被引量:12
  • 2于峥嵘,李淳德,刘宪义.恩再适治疗腰椎管狭窄症术后残余神经症状的临床观察[J].中国医药,2006,1(12):746-748. 被引量:20
  • 3[1]Siniscalco D,Rossi F,Maione S.Molecular approaches for neuropathic pain treatment[J].Curr Med Chem,2007,14(16):1783-1787
  • 4[2]De Reuck J,Deeoo D,Vanderdonckt P,et al.A double-blind study of neurotropin in patients with acute ischemic stroke[J].Acta Neurol Scand,t994,89(5):329-335
  • 5[3]White FA,Jung H,Miller RJ.Chemokines and the pathophysiology of neuropathic pain[J].Proe Natl Acad Sci U S A,2007,104(51):20151-20158
  • 6Repetto L. Greater risks of chemotherapy toxicity in elderly patients with cancer. J Support Oncol,2003,1 ( Suppl 2 ) : 18-24.
  • 7De Jongh FE ,van Veen RN ,Veltman SJ et al. Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients. Br J Cancer,2003,88 : 1199-206.
  • 8Jamieson SM, Liu J, Hsu T, et al. Paclitaxel induces nucleolar enlargement in dorsal root ganglion neurons in vivo reducing oxaliplatin toxicity. Br J Cancer,2003,88:1942-1947.
  • 9Guastalla JP 3rd, Dieras V. The taxanes:toxicity and quality of life considerations in advanced ovarian cancer. Br J Cancer,2003,89 ( Suppl 3) :S16-22.
  • 10Markman M ,Glass T,Smith HO,et al. Phase Ⅱ trial of single agent carboplatin followed by dose-intense paclitaxel, followed by maintenance paclitaxel therapy in stage Ⅳ ovarian, fallopian tube, and peritoneal cancers : a Southwest Oncology Group trial. Gynecol Oncol, 2003,88 :282-288.

共引文献55

同被引文献119

引证文献14

二级引证文献78

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部